Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Fintech PR

Cognizant Unveils Advanced Artificial Intelligence Lab to Accelerate AI Research and Innovation




With 75 issued and pending patents, the lab will launch with a team of dedicated AI researchers and developers; focus will be on research, innovation and production of cutting-edge AI systems

TEANECK, N.J., March 7, 2024 /PRNewswire/ — Cognizant (Nasdaq: CTSH), a leading global technology company, today announced the launch of an Advanced Artificial Intelligence (AI) Lab. The lab, based in San Francisco, will focus on advancing the science and practice of AI through innovation and development of intellectual property and AI-enablement technologies. Staffed by a team of researchers and developers, including AI pioneers and PhDs, the lab will collaborate with research institutions, customers, and startups and already has 75 issued and pending patents that provide a differentiated foundation on which to build cutting edge AI solutions. The lab is part of the commitment Cognizant announced last year to invest $1 billion in generative AI (gen AI) over the next three years.

The launch of Cognizant’s Advanced AI Lab comes at a time when enterprises are rapidly working to understand the impact of AI and meet expanding expectations around its promise. Recent research has shown more than half (66 percent) of executives are ambivalent or dissatisfied with their company’s progress on AI and gen AI, and most executives (85 percent) plan to increase spending on AI and gen AI in 2024. Longer term, Cognizant and Oxford Economics’ recent study found gen AI could inject up to $1 trillion to the U.S. economy by 2032.

“As AI rapidly evolves into mainstream use, Cognizant is continually pushing boundaries through strategic partnerships, training programs and platform investments to be an AI-first company,” said Cognizant CEO Ravi Kumar S. “With the launch of Cognizant’s Advanced AI Lab, we’re progressing this effort by investing in state-of-the-art core AI research that establishes our position at the forefront of innovation and our industry. Because we own the client solutioning relationship from end to end, we have a unique line of sight into businesses, industries, and their AI needs. We’re putting dedicated focus on AI research and development to lay the groundwork for better business outcomes and a better future.”

By harnessing the power of Large Language Models (LLMs) as capable knowledge workers, the lab’s researchers and developers will use the Cognizant Neuro™ AI platform to orchestrate LLMs into decision-making AI systems that can positively impact and optimize business outcomes. Moving beyond simple prompt engineering and fine-tuning, these customized AI applications will be designed to support higher value outcomes — from strategic board-level business decisions to enterprise operations including financial, sales, product, and IT support, to day-to-day productivity of individual employees.  

“Cognizant’s Advanced AI Lab is an important partner for us in the research community, and we’ve been fast at work with them already working on simulating brain dynamics in healthy and patient populations,” said Dr. Manish Saggar, Assistant Professor and Director of Brain Dynamics Lab at Stanford University School of Medicine. “I’m excited about the progress we’re making together, as well as its potential impact on not only advancing science but also for developing novel interventions for mental health disorders.”

Specifically, Cognizant’s Advanced AI Lab will focus on the following areas:

  • Researching, designing, evaluating, building, and showcasing innovative AI solutions for business productivity and decision making across various domains
  • Collaborating with external stakeholders, including research institutions, customers, and startups, and engaging in AI-for-good research projects
  • Evangelizing gen AI-enabled decision-making solutions globally, and strengthening Cognizant as a knowledge hub for published, peer-reviewed research on AI
  • Partnering across Cognizant’s business lines and practices to train and upskill associates on new AI solutions as they become available through the Cognizant Neuro™ AI platform
  • Fostering an environment of continuous learning, innovation, and knowledge sharing

The lab will be led by AI entrepreneur and inventor, Babak Hodjat, with AI research activities under the supervision of University of Texas at Austin AI Professor and neuroevolution pioneer, Risto Miikkulainen. In just the last year, their team of researchers and developers have already published 14 papers in academic venues, and they received the Best Pathway to Impact Award at the NeurIPS 2023 Climate Change Workshop for the paper, Discovering Effective Policies for Land-Use Planning.

In addition to the launch of Cognizant’s Advanced AI Lab, Cognizant is supporting enterprise AI adoption through its AI Innovation Studios in London, New York, San Francisco, Dallas, and Bengaluru. These studios serve as inspiration and co-innovation spaces that bring clients and associates together to identify and collaborate on new business solutions.

Cognizant is dedicated to maintaining the highest standards for responsible and ethical AI, focusing on safety, security, privacy, transparency, and inclusion. For additional details on Cognizant’s approach to gen AI and the company’s commitment to responsible AI, visit here. Cognizant also develops research and insights that help leaders make informed decisions to fuel their companies’ success. In partnership with Oxford Economics, Cognizant recently published a study on the economic impact of AI, “New World, New Work,” and intends to release further research on AI’s impact on productivity, tasks, skills, jobs and occupations.

About Cognizant
Cognizant (Nasdaq: CTSH) engineers modern businesses. We help our clients modernize technology, reimagine processes and transform experiences so they can stay ahead in our fast-changing world. Together, we’re improving everyday life. See how at or @cognizant.

Risto Miikkulainen, Associate Vice President, Evolutionary AI at Cognizant and University of Texas at Austin AI Professor


New Cognizant Logo

Photo –
Photo –
Logo –

Cision View original content:

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Fintech PR

Invitation to presentation of EQT AB’s Q1 Announcement 2024




STOCKHOLM, April 5, 2024 /PRNewswire/ — EQT AB’s Q1 Announcement 2024 will be published on Thursday 18 April 2024 at approximately 07:30 CEST. EQT will host a conference call at 08:30 CEST to present the report, followed by a Q&A session.

The presentation and a video link for the webcast will be available here from the time of the publication of the Q1 Announcement.

To participate by phone and ask questions during the Q&A, please register here in advance. Upon registration, you will receive your personal dial-in details.

The webcast can be followed live here and a recording will be available afterwards.

Information on EQT AB’s financial reporting

The EQT AB Group has a long-term business model founded on a promise to its fund investors to invest capital, drive value creation and create consistent attractive returns over a 5 to 10-year horizon. The Group’s financial model is primarily affected by the size of its fee-generating assets under management, the performance of the EQT funds and its ability to recruit and retain top talent.

The Group operates in a market driven by long-term trends and thus believes quarterly financial statements are less relevant for investors. However, in order to provide the market with relevant and suitable information about the Group’s development, EQT publishes quarterly announcements with key operating numbers that are relevant for the business performance (taking Nasdaq’s guidance note for preparing interim management statements into consideration). In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published. Finally, EQT also publishes an annual report including sustainability reporting.

Olof Svensson, Head of Shareholder Relations, +46 72 989 09 15
EQT Shareholder Relations, [email protected]

Rickard Buch, Head of Corporate Communications, +46 72 989 09 11
EQT Press Office, [email protected], +46 8 506 55 334

This information was brought to you by Cision,c3956826

The following files are available for download:

Invitation to presentation of EQT AB’s Q1 Announcement 2024,c3285895

EQT AB Group


View original content:

Continue Reading

Fintech PR

Kia presents roadmap to lead global electrification era through EVs, HEVs and PBVs



  • Kia drives forward transformation into ‘Sustainable Mobility Solutions Provider’
  • Roadmap enables Kia to proactively respond to uncertainties in mobility industry landscape, including changes in EV market
  • Company to expand EV line-up with more models; enhance HEV line-up to manage fluctuation in EV demand
    • Goal to sell 1.6 million EVs annually in 2030, introducing 15 models
    • PBV to play a key role in Kia’s growth, targeting 250,000 PBV sales annually by 2030 with PV5 and PV7 models
  • Kia to invest KRW 38 trillion by 2028, including KRW 15 trillion for future business
  • 2024 business guidance : KRW 101 tln in revenue with KRW 12 tln in operating profit; operating profit margin of 11.9% on sales of 3.2 million units globally
  • CEO reaffirms Kia’s commitment to ESG management

SEOUL, South Korea, April 5, 2024 /PRNewswire/ — Kia Corporation (Kia) today shared an update on its future strategies and financial targets at its CEO Investor Day in Seoul, Korea.

Based on its innovative achievements in the years since the announcement of mid-to-long-term business initiatives, Kia is focusing on updating its 2030 strategy announced last year and further strengthening its business strategy in response to uncertainties across the global mobility industry landscape.

During the event, Kia updated its mid-to-long-term business strategy with a focus on electrification, and its PBV business. Kia reiterated its 2030 annual sales target of 4.3 million units, including 1.6 million units of electric vehicles (EVs). The 2030 4.3 million annual sales target is 34.4 percent higher than the brand’s 2024 annual goal of 3.2 million units.

The company also plans to become a leading EV brand by selling a higher percentage of electrified models among its total sales, including hybrid electric vehicles (HEV), plug-in hybrid (PHEV), and battery EVs, projecting electrified model sales of 2.48 million units annually or 58 percent of Kia’s total sales in 2030.

“Following our successful brand relaunch in 2021, Kia is enhancing its global business strategy to further the establishment of an innovative EV line-up and accelerate the company’s transition to a sustainable mobility solutions provider,” said Ho Sung Song, President and CEO of Kia. “By responding effectively to changes in the mobility market and efficiently implementing mid-to-long-term strategies, Kia is strengthening its brand commitment to the wellbeing of customers, communities, the global society, and the environment.”

Photo –

Cision View original content to download multimedia:

Continue Reading

Fintech PR

BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update




VANCOUVER, BC, April 4, 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the “Company“) is providing this bi-weekly update on the status of the management cease trade order granted on February 29, 2024 (the “MCTO“), by its principal regulator, the Ontario Securities Commission (the “OSC“), under National Policy 12-203 – Management Cease Trade Orders (“NP 12-203“), following the Company’s announcement on February 21, 2024 (the “Default Announcement“), that it was unable to file its audited annual financial statements for the year ended October 31, 2023, its management’s discussion and analysis of financial statements for the year ended October 31, 2023, its annual information form for the year ended October 31, 2023, and related filings (collectively, the “Required Annual Filings“). Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.

As a result of the delay in filing the Required Annual Filings, the Company was unable to file its interim financial statements for the three months ended January 31, 2024, its management’s discussion and analysis of financial statements for the three months ended January 31, 2024, and related filings (collectively, the “Required Interim Filings“). Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.

The Company anticipates filing the Required Annual Filings by April 30, 2024. The auditor of the Company requires additional time to complete its audit of the Company, including the Company’s recent acquisition of all intellectual property, immunotherapeutics platform technologies, and clinical stage assets of the former IMV Inc. that closed on February 16, 2024. In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.

Except as herein disclosed, there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the alternative information guidelines under NP 12-203 and issue bi-weekly default status reports for so long as the delay in filing the Required Annual Filings and/or Required Interim Filings is continuing, each of which will be issued in the form of a press release; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the Required Annual Filings and Required Interim Filings; (iii) the Company is not subject to any insolvency proceedings; and (iv) there is no material information concerning the affairs of the Company that has not been generally disclosed.

About BioVaxys Technology Corp.

BioVaxys Technology Corp. (, a biopharmaceuticals company registered in British Columbia, Canada, is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX™ immune-educating technology platform and it’s HapTenix© ‘neoantigen’ tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The Company’s clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using it proprietary HapTenix© ‘neoantigen’ tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer. The Company is also capitalizing on its tumor immunology know-how and creation of a unique library of T-lymphocytes & other datasets post-vaccination with its personalized immunotherapeutic vaccines to utilize predictive algorithms and other technologies to identify new targetable tumor antigens. BioVaxys common shares are listed on the CSE under the stock symbol “BIOV” and trade on the Frankfurt Bourse (FRA: 5LB) and in the US (OTCQB: BVAXF). For more information, visit and connect with us on X and LinkedIn.


Signed “James Passin
James Passin, Chief Executive Officer
Phone: +1 646 452 7054

Logo –

Cision View original content:

Continue Reading